Elevance Health Q1 2024 Adj EPS $10.64 Beats $10.53 Estimate, Sales $42.273B Miss $42.626B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elevance Health (ELV) reported Q1 2024 adjusted EPS of $10.64, surpassing the $10.53 estimate, marking a 12.47% increase from last year. However, their sales of $42.273B fell short of the $42.626B estimate, a slight 0.90% increase from the previous year.

April 18, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elevance Health reported a higher-than-expected Q1 2024 EPS of $10.64 but missed sales estimates with $42.273B.
The positive earnings surprise could support ELV's stock price due to the beat on EPS estimates, indicating operational efficiency and profitability. However, the miss on sales estimates could temper investor enthusiasm, suggesting potential challenges in revenue growth. The mixed results present a neutral short-term outlook, as the positive impact of exceeding EPS expectations may be offset by the slight disappointment in sales performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100